AAV Purification: Methods, Process Steps, and Downstream Challenges

Adeno-associated virus (AAV) vectors are central to many gene therapy strategies because they combine a strong safety profile with broad tissue tropism and the ability to support sustained transgene expression. Since the first approved AAV-based therapy, interest in these vectors has continued to grow across both therapeutic and vaccine applications.^1,2,3

That potential depends heavily on purity. Empty capsids, host cell impurities and other contaminants can reduce performance, complicate analytics and introduce safety or dosing concerns. By contrast, a well-purified AAV preparation contains a higher proportion of functional vectors, helping improve consistency, transduction efficiency and overall product quality.^4,5,6

AAV purification is the downstream process used to remove debris, reduce empty capsids and enrich full viral particles after production. Teams typically use combinations of chromatography, ultracentrifugation and filtration to build workflows that fit the serotype, scale and quality requirements of the program.^7,8

Overview

AAV purification is the downstream process used to isolate full, functional adeno-associated virus particles from a harvest that also contains host cell proteins, nucleic acids, aggregates, process residues and empty capsids. The goal is to improve purity, potency and consistency so the final material is suitable for research, preclinical development or clinical manufacturing.

Because AAV products vary by serotype, production system, scale and intended use, no single purification workflow fits every program. Most teams combine clarification, concentration, capture, polishing and formulation steps to balance purity, yield, scalability and cost.

What is the AAV purification process?

A successful AAV purification process follows a series of well-defined steps to ensure the final product is a highly purified, concentrated AAV vector suitable for safe and effective gene therapy applications.⁷

Harvesting of the AAV vectors

The method for collecting the viral harvest following AAV vector production within host cells depends on the specific AAV serotype. For serotypes like AAV8 and 9, the AAV vectors are present in the cell culture supernatant.⁹ In contrast, other serotypes necessitate cell lysis to release the encapsulated AAV vectors.

Clarification and Filtration

This step removes cellular debris and large contaminants from the harvest using techniques such as centrifugation and filtration, yielding a clarified solution containing the AAV vectors.

Concentration and Purification

This is the core purification step, in which the clarified solution undergoes further processing via chromatography or ultracentrifugation to concentrate and purify the AAV vectors. This step removes impurities, such as empty capsids and other unwanted components.

Formulation and Storage

The purified AAV vectors are then formulated with specific buffers and excipients to ensure stability and functionality during storage and delivery.¹⁰ Finally, the formulated AAV vector preparation is filled into vials and stored under controlled conditions until administration.

Maintaining aseptic conditions throughout the process is crucial to preventing contamination. Assays are also performed at various stages to monitor AAV vector yield and purity.

What AAV purification methods are used most often?

There are two main types of AAV purification techniques:

Ultracentrifugation-based methods

This method utilizes high-speed centrifugation to separate and isolate AAVs from the solution based on their buoyant density or sedimentation rates.

The two most common ultracentrifugation methods are:

Cesium Chloride (CsCl) Gradient Ultracentrifugation

In this traditional method, the CsCl solution forms a density gradient during high-speed centrifugation. AAV vectors, along with other particles in the sample, such as empty capsids and cellular debris, sediment at distinct positions within the gradient based on their individual densities, facilitating their separation.¹¹

Iodixanol Gradient Ultracentrifugation

Like CsCl, this method separates particles based on their buoyant density in a pre-formed gradient. However, it utilizes iodixanol, a synthetic, non-ionic gradient medium.¹²

This is a relatively safer technique because iodixanol is less toxic than CsCl. Iodixanol is less dense than CsCl, thus offering a gentler separation environment for AAV vectors.¹³ However, it may not be as efficient for some AAV serotypes as CsCl gradients.¹³

Chromatography-based methods

This method exploits the differential interaction of AAV vectors with a chromatography resin. These resins have a specific surface chemistry that selectively binds AAVs based on properties such as size, charge or affinity for specific ligands. AAVs are passed through a column packed with the resin. Contaminants with weak interactions flow through the column first, while AAVs bind to the resin. Subsequent elution steps with specific buffers or solutions detach the AAVs from the resin, thereby purifying them.

The three main chromatography methods are:

Ion-exchange Chromatography (IEX)

This method separates particles based on their net surface charge. AAV capsids exhibit a distinct surface charge distribution, facilitating their effective separation from empty capsids and host cell proteins.¹⁴

IEX is a common choice for initial purification of AAV vectors because it is well-established, cost-effective and capable of handling large sample volumes. However, it may not achieve sufficient purity for all AAV-based gene therapy applications.²

Affinity Chromatography

This method offers highly specific separation based on the interaction between an immobilized ligand and a target molecule. In AAV purification, the ligand binds specifically to a protein on the AAV capsid.

Affinity Chromatography is highly efficient at separating AAV serotypes or removing empty capsids with charges similar to those of full vectors. However, developing and using specific ligands is expensive and may not be scalable for large-volume production.

Size-Exclusion Chromatography (SEC)

This method separates particles based on their size and shape. In AAV purification, it gently separates AAV capsids from residual aggregates or contaminants of different sizes, preserving AAV vector functionality. It is often used as a final polishing step after the main purification by IEX or affinity chromatography.¹⁵

Filtration techniques

Filtration techniques play a crucial role in purifying AAV vectors by removing unwanted particles and contaminants at various stages of the process.

The two most common filtration techniques are:

Tangential Flow Filtration (TFF)

This is a pressure-driven process in which the feed stream flows tangentially across a semi-permeable membrane, allowing the filtrate (desired product) to permeate through while retaining larger particles and impurities in the retentate stream.¹⁶

This filtration technique is versatile enough to be used for clarification, concentration and buffer exchange. It is adaptable for both small and large-scale AAV production and is relatively gentle on AAV vectors compared to other methods. However, selecting the membrane is crucial to ensure efficient AAV passage while retaining impurities, as an improper choice can lead to AAV vector loss.¹⁶

Depth Filtration

This method employs a depth filter medium with a tortuous path to capture impurities.¹⁷ During this process, the feed stream flows through the filter and particles exceeding the size of the filter pores become trapped within the media.

Compared to TFF, depth filtration offers a simpler, less expensive approach, particularly suited for initial clarification steps due to its high capacity to capture large particles.⁷ However, its versatility is limited as it primarily functions in this initial role. This technique is more susceptible to clogging, potentially requiring frequent filter changes.¹⁸ Additionally, compared to TFF, there is a greater risk of AAV vector loss due to adsorption onto the filter media.

AAV purification methods at a glance

Featured Product

How do you choose the right AAV purification method?

There is no single best method for AAV purification. The right approach depends on vector properties, production scale, downstream requirements and quality targets. In practice, teams choose methods that deliver the needed balance of yield, purity, scalability and process control.

Vector Characteristics

• Different AAV serotypes possess distinct physical properties, such as surface charges and affinity for cellular receptors. These variations can affect the selection of chromatography resins or membranes used for purification separations.
• AAV vectors primarily exist as single particles, but aggregation can occur, forming particles of varying sizes. Size-exclusion chromatography can be effectively optimized to separate the predominant size of the AAV vector population from aggregates or other contaminants with different sizes.
• Stability considerations also play a role. Some AAV serotypes exhibit greater stability than others under specific conditions, such as exposure to certain buffers or pH ranges. This necessitates judicious selection of purification methods and protocols, as harsh conditions or prolonged processing times might not be suitable for less stable serotypes.¹⁹

Scale of Production

• Techniques like iodixanol gradient centrifugation or small-scale chromatography columns might be sufficient for research purposes or initial development.²⁰
• Scalability is crucial for commercial AAV production. Chromatography methods are generally preferred for their greater scalability compared to ultracentrifugation, which can be time-consuming for large volumes.²⁰

Downstream Processing Requirements

• If the AAV vector solution needs to be concentrated after purification, techniques like tangential flow filtration (TFF) can be integrated into the purification process.²¹
• The AAV vector might need to be suspended in a specific buffer for downstream applications like gene therapy. Diafiltration using TFF allows for buffer exchange while concentrating the AAV vector solution.²¹
• Sterile filtration might be required as a final step for clinical-grade AAV vectors.²² This ensures the absence of microorganisms in the final product.

What are the biggest AAV purification challenges?

AAV purification has improved significantly, but several technical and manufacturing challenges remain. The biggest issues include separating empty capsids from full particles, maintaining recovery while increasing purity and scaling processes without losing consistency.

Key limitations to keep in mind

• Empty/full capsid resolution is still difficult: Many workflows reduce impurities effectively, but do not fully separate empty capsids from genome-containing particles without additional optimization
• Serotype behavior is not uniform: A resin, membrane or gradient condition that works well for one capsid may underperform with another
• Scale can change performance: Recovery, pressure behavior, residence time and impurity clearance may shift substantially during scale-up
• Higher purity can reduce recovery: Aggressive polishing steps may improve impurity profiles while lowering final vector yield
• Analytical alignment is essential: Without robust assays, it is difficult to confirm whether a purification change truly improved product quality

Balancing Product Yield and Purity

Balancing high yield and high purity during AAV purification remains a significant challenge. While a high yield facilitates dose optimization and broader clinical trials, achieving high purity is essential for efficient transduction, minimal immune response and optimal vector biodistribution. Unfortunately, high-resolution purification techniques often come at the expense of yield by removing a larger portion of the AAV vector population, including some functional vectors.

Researchers address this challenge in two ways:

1. They employ multi-step approaches, such as an initial step like ion exchange chromatography to remove larger contaminants, followed by a high-resolution technique like size exclusion chromatography for final polishing.¹⁵'²³
2. They address inefficiencies during purification, such as incomplete capture or transfer losses, by refining parameters like buffer composition, resins or centrifugation conditions.²⁴

Furthermore, ongoing research seeks to develop novel methods that minimize yield losses while maximizing purity.²⁴ Additionally, a high-quality viral harvest, achieved through optimized production cell lines and efficient clarification steps, contributes to a purer harvest with a higher concentration of functional AAV vectors, ultimately facilitating a more streamlined purification process.²⁵

Scalability

Scaling up AAV purification from research to commercial production presents several challenges:²⁶

• Multi-step purification protocols often struggle to maintain efficiency and minimize losses during large-scale processing. These protocols, optimized for smaller batches, may not translate well to larger volumes.
• Large-scale AAV production requires a sufficient viral harvest. Scaling up cell culture to generate enough AAV vectors can strain resources for media, bioreactors and qualified personnel.
• Upgrading equipment is necessary to handle significant harvests. This necessitates investment in larger chromatography columns, high-throughput centrifuges and other specialized processing equipment.
• Rigorous process validation for larger scales is crucial. This ensures consistent product quality and regulatory compliance.

Automation emerges as a critical solution by streamlining processes, minimizing errors and potentially reducing labor costs, ultimately enabling a more efficient, cost-effective path to large-scale production of high-purity AAV vectors.²⁷

Cost-effectiveness

AAV purification faces significant cost hurdles due to several factors:²⁸

• It requires the use of expensive buffers, chromatography resins and other specialized consumables.
• Inefficient purification processes that result in high losses of AAV vectors further strain financial resources.
• Downstream processing steps such as formulation and filling also contribute to the overall cost burden.
• Upfront investment in large-scale facilities adds another layer of cost consideration.
• Labor costs associated with manual processing further exacerbate this issue.

These factors collectively contribute to a high cost per dose of the final gene therapy product.

Addressing these challenges necessitates a multi-pronged approach. Exploring cost-effective alternatives for consumables and developing continuous processing techniques offer promising solutions. Furthermore, standardizing AAV purification protocols and automating steps can minimize errors and improve efficiency, ultimately leading to cost savings.

Where does AAV purification matter most in real-world applications?

In early research, purification workflows are often designed for speed and flexibility, enabling teams to compare serotypes, screen constructs and generate material for in vitro and in vivo studies. At this stage, methods such as iodixanol gradients or smaller chromatography systems may be appropriate because they can produce workable material quickly, even if the process is not yet optimized for manufacturing scale.

In preclinical and clinical development, the emphasis shifts toward reproducibility, impurity control and process knowledge. Purification decisions can influence empty-to-full capsid ratios, residual host cell impurities, formulation compatibility and batch-to-batch consistency, all of which affect analytical characterization and comparability studies.

As programs move closer to the clinic, scalable chromatography and filtration strategies typically become more important because they support validation, technology transfer and tighter process control.

For commercial manufacturing, purification is closely tied to the cost of goods, facility fit and supply reliability. A process that performs well at bench scale may become impractical if it requires excessive manual handling, specialized consumables or low-throughput equipment.

Real-world process design, therefore, focuses not only on purity targets but also on cycle time, operator burden, resin or membrane lifetime and the ability to support larger campaigns without compromising vector quality.

Conclusion

AAV purification is no longer just a downstream cleanup step. It is a core process decision that affects vector quality, manufacturability, cost and clinical readiness. As AAV programs move toward larger-scale and more complex applications, purification strategies that improve control, scalability and consistency will be critical to delivering high-quality vectors with confidence.

Reference

1. Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78.
2. Nass SA, Mattingly MA, Woodcock DA, Burnham BL, Ardinger JA, Osmond SE, et al. Universal method for the purification of recombinant AAV vectors of differing serotypes. Mol Ther Methods Clin Dev. 2018;9:33-46.
3. Nieto K, Salvetti A. AAV vectors vaccines against infectious diseases. Front Immunol. 2014;5:69616.
4. McColl-Carboni A, Dollive S, Laughlin S, Lushi R, MacArthur M, Zhou S, et al. Analytical characterization of full, intermediate, and empty AAV capsids. Gene Ther. 2024:1-0.
5. Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V, et al. High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther. 2010;17(4):503-10.
6. Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, et al. Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat Commun. 2015;6(1):6246.
7. Adams B, Bak H, Tustian AD. Moving from the bench towards a large scale, industrial platform process for adeno‐associated viral vector purification. Biotechnol Bioeng. 2020;117(10):3199-211.
8. Richter K, Wurm C, Strasser K, Bauer J, Bakou M, VerHeul R, et al. Purity and DNA content of AAV capsids assessed by analytical ultracentrifugation and orthogonal biophysical techniques. Eur J Pharm Biopharm. 2023;189:68-83.
9. Vandenberghe LH, Xiao R, Lock M, Lin J, Korn M, Wilson JM. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther, 2010;21(10):1251-7.
10. Srivastava A, Mallela KM, Deorkar N, Brophy G. Manufacturing challenges and rational formulation development for AAV viral vectors. J Pharm Sci. 2021;110(7):2609-24.
11. Burova E, Ioffe E. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. Gene Ther. 2005;12(1):S5-17.
12. Crosson SM, Dib P, Smith JK, Zolotukhin S. Helper-free production of laboratory grade AAV and purification by iodixanol density gradient centrifugation. Mol Ther Methods Clin Dev. 2018;10:1-7.
13. El Andari J, Grimm D. Production, processing, and characterization of synthetic AAV gene therapy vectors. Biotechnol J. 2021;16(1):2000025.
14. Heldt CL, Areo O, Joshi PU, Mi X, Ivanova Y, Berrill A. Empty and Full AAV Capsid Charge and Hydrophobicity Differences Measured with Single-Particle AFM. Langmuir. 2023;39(16):5641-8.
15. McIntosh NL, Berguig GY, Karim OA, Cortesio CL, De Angelis R, Khan AA, et al. Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering. Sci Rep. 2021;11(1):3012.
16. Grzenia DL, Carlson JO, Wickramasinghe SR. Tangential flow filtration for virus purification. J Memb Sci. 2008;321(2):373-80.
17. Griffiths IM, Mitevski I, Vujkovac I, Illingworth MR, Stewart PS. The role of tortuosity in filtration efficiency: A general network model for filtration. J Memb Sci. 2020;598:117664.
18. Mendes JP, Fernandes B, Pineda E, Kudugunti S, Bransby M, Gantier R, et al. AAV process intensification by perfusion bioreaction and integrated clarification. Front Bioeng Biotechnol. 2022;10:1020174.
19. Khanal O, Kumar V, Jin M. Adeno-associated viral capsid stability on anion exchange chromatography column and its impact on empty and full capsid separation. Mol Ther Methods Clin Dev. 2023;31.
20. Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther. 2010;21(10):1259-71.
21. Miyaoka R, Tsunekawa Y, Kurosawa Y, Sasaki T, Onodera A, Sakamoto K, et al. Development of a novel purification method for AAV vectors using tangential flow filtration. Biotechnol Bioeng. 2023;120(11):3311-21.
22. Mandel RJ, Burger C, Snyder RO. Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp Neurol. 2008;209(1):58-71.
23. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6(6):973-85.
24. Kilgore R, Minzoni A, Shastry S, Smith W, Barbieri E, Wu Y, LeBarre JP, et al. The downstream bioprocess toolbox for therapeutic viral vectors. J Chromatogr A. 2023;1709:464337.
25. Benskey MJ, Sandoval IM, Manfredsson FP. Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield. Hum Gene Ther. 2016;27(1):32-45.
26. Jiang Z, Dalby PA. Challenges in scaling up AAV-based gene therapy manufacturing. Trends Biotechnol. 2023;41(10):1268-1281.
27. Fu X, Williams A, Bakhshayeshi M, Pieracci J. Leveraging high-throughput purification to accelerate viral vector process development. J Chromatogr A. 2022;1663:462744.
28. Lyle A, Stamatis C, Linke T, Hulley M, Schmelzer A, Turner R, Farid SS. Process economics evaluation and optimization of adeno‐associated virus downstream processing. Biotechnol Bioeng. 2023.
29. Rodrigues GA, Shalaev E, Karami TK, Cunningham J, Slater NK, Rivers HM. Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res. 2019;36(2):29.